RE:RE:RE:RE:RE:RE:RE:RE:RE:NewsCouldn`t say Oliminer but TLD-1433 has been in GLP (toxicity) at Roswell for well over a month and Rutherrin was in non-GLP (pre-toxicity) in Toronto on the 21st of April so possibly at about the same stages by now.
Whereas the work on GBM is entirely pioneering believe that Roswell may have some previous experience with administration and activation of Photofrin in the lung and certainly a clear understanding of how they will instill the compound and activate it. Their absolute priority is the welfare of their patients and they will advance anything that has a good chance in conditions with such poor prognoses as NSCLC and Mesothelioma.In other words given good pre-Clinical results and the level of unmet need in these indications they are unlikely to hang around and may well be in the Clinic first.